Aegerion Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 91   

Articles published

AEGR 24.87 +0.36 (1.47%)
price chart
Why Aegerion Pharmaceuticals, Inc. Stock Collapsed in October
What: Shares of Aegerion Pharmaceuticals (NASDAQ: AEGR ) , a biopharmaceutical company focused on developing drugs to treat rare diseases, collapsed in October and lost 40% of their value, based on data from S&P Capital IQ, after the company ...
Aegerion Pharmaceuticals Acquires Myalept(TM) From AstraZeneca  GlobeNewswire (press release)
Aegerion Pharma Buys Drug From AstraZeneca for $325M  Mergers & Acquisitions - The Middle Market
Related articles »  
Perilous Reversal Stock: Aegerion Pharmaceuticals (AEGR)
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States.
Stock in Focus : Aegerion Pharmaceuticals Inc (NASDAQ:AEGR)  Street Report
Brokerages Set Aegerion Pharmaceuticals Price Target at $44.29 (NASDAQ ...  Ticker Report
Short Interest of Aegerion Pharmaceuticals, Inc. Increases by 0.1%
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) has shown a rise of 0.1% or 6,014 shares in the short positions. The bets have increased to 7,274,295 shares on December 31,2014 from 7,268,281 shares on December 15,2014.
Report: Holders Push For Sale At Aegerion Pharmaceuticals
Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) is getting pushed toward a sale by several major shareholders, according to a report Wednesday.
Aegerion Pharmaceuticals Reports Preliminary 2014 Net Product Sales, Its ...  CNNMoney
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program  Nasdaq
Why Aegerion Pharmaceuticals Inc. Shares Briefly Tumbled
What: Shares of Aegerion Pharmaceuticals (NASDAQ: AEGR ) , a biopharmaceutical company developing therapies to treat rare and fatal diseases, tumbled briefly by as much as 18% after reporting its fourth quarter earnings results before the opening bell.
Related articles »  
Aegerion Pharmaceuticals (AEGR) Stock Downgraded Today at Jefferies
"We rate AEGERION PHARMACEUTICALS INC (AEGR) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared ...
Aegerion Falls On Disappointing Earnings  Bidness ETC
Aegerion Pharmaceuticals Plunges to New 52-Week Low  24/7 Wall St.
Related articles »  
Aegerion Pharmaceuticals (AEGR) Is Today's Dead Cat Bounce Stock
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States.
Aegerion Downgraded As Stock Sheds 41% On Disappointing Q3 Results  Bidness ETC
Meet The Biopharma Stock That Lost 34% Last Week  Benzinga
Related articles »  
Aegerion Pharmaceuticals, Inc. (AEGR): Broadfin Boosts Stake Getting on Board ...
Kevin Kotler's New York-based fund Broadfin Capital has boosted its position in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR).
Related articles »  
Aegerion Pharmaceuticals, Inc. (AEGR) & The GEO Group Inc (GEO): Scopia ...
Scopia Capital Management has disclosed in a recent regulatory filing with the Security and Exchange Commission that it has acquired 4.2 million shares of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a $900 million market cap biopharmaceutical ...
Why Aegerion Pharmaceuticals (AEGR) Stock Is Down Today  TheStreet.com
Related articles »  
Aegerion Pharmaceuticals Inc. (AEGR), Cytori Therapeutics Inc (CYTX): Scopia ...
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) continues to feel hedge funds' bullishness. Not only did Steve Cohen's Point72 Asset Management disclose an increase in its exposure to the company today, but also Matt Sirovich and Jeremy Mindich's ...
Related articles »